Hematology-Oncology Department, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.
Hematology-Oncology Department, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.
Semin Oncol. 2020 Feb;47(1):73-84. doi: 10.1053/j.seminoncol.2020.02.009. Epub 2020 Mar 9.
Soft-tissue sarcomas (STS) are a group of rare mesenchymal tumors that constitutes ∼1% of all solid tumors. It remains a rare tumor which lacks effective treatment options. Precision oncology may be of interest in this regard by identifying potential targets for emerging novel therapies. Neurotrophic receptor tyrosine kinase (NTRK) fusions are rare oncogenic driver mutations found in a broad range of common and rare tumor subtypes including STS. The recent approvals of NTRK inhibitors (larotrectinib and entrectinib) represent new therapeutic options in the drug armamentarium especially valuable in advanced STS given the paucity of treatment options and the generally poor prognosis of these tumors. We review the methods used to detect NTRK fusions in STS with focus on incidence, diagnosis and management of these rare and intriguing oncogenic targets.
软组织肉瘤（STS）是一组罕见的间叶肿瘤，占所有实体肿瘤的 1%左右。它仍然是一种罕见的肿瘤，缺乏有效的治疗选择。精准肿瘤学可能对此感兴趣，通过确定新兴新型治疗方法的潜在靶点。神经营养受体酪氨酸激酶（NTRK）融合是一种罕见的致癌驱动突变，存在于广泛的常见和罕见肿瘤亚型中，包括 STS。NTRK 抑制剂（拉罗替尼和恩曲替尼）的最近批准代表了药物治疗中的新的治疗选择，特别是在晚期 STS 中具有重要价值，因为这些肿瘤的治疗选择有限，且预后一般较差。我们回顾了在 STS 中检测 NTRK 融合的方法，重点是这些罕见而有趣的致癌靶点的发生率、诊断和治疗。
